HEMGENIX FUNDAMENTALS EXPLAINED

Number of eligible patients: CDEC mentioned the uncertainty in the amount of sufferers with moderately extreme to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who are categorised as owning moderate or reasonable ailment could have a significant